Bayer Battles Generic Yasmin Hopeful In Fed. Circ.

Law360, Washington (December 7, 2011, 4:54 PM EST) -- Bayer Healthcare Pharmaceuticals Inc. sought to persuade the Federal Circuit on Wednesday that it has a valid case to block generics makers from introducing a version of its oral contraceptive Yasmin, saying its patent covers all uses of the drug.

In September 2010, a New York federal judge ruled in favor of Watson Laboratories Inc. and Sandoz Inc. in Bayer's Hatch-Waxman Act suit, saying the disputed claim of U.S. Patent 5,569,652 does not cover a use approved by the U.S. Food and Drug Administration.

Bayer argued...
To view the full article, register now.